Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ:AMAM), today announced that it will host an in-person key opinion leader (KOL) event during the European Society for Medical Oncology (ESMO) Congress 2023. The event will take place on Sunday, October 22, 2023 from 8:00pm – 10:00pm CEST (2:00pm – 4:00pm ET) at the Santo Mauro Hotel in Madrid, Spain. Discussions will feature preliminary safety, efficacy, and pharmacokinetic (PK) data from APEX-01 (NCT04662580), a first-in-human study evaluating ARX517 in prostate cancer patients, which will be presented for the first time at ESMO 2023.
The event will showcase presentations from prostate cancer experts, Scott T. Tagawa, MD, MS, FACP, FASCO (Weill Cornell Medicine), Oliver Sartor, MD (Mayo Clinic), John Shen, MD (UCLA Health), and pharmacokinetics expert Rakesh Dixit, PhD, DABT (Regis Biosciences; BIONAVIGEN Oncology).
To register for the event, please click here. For those who are unable to attend in person, a virtual webcast of the event will be available at the same link. A replay of the event will be available on the Investor Relations section of the Ambrx website (www.ambrx.com) after the event. Corresponding presentation materials will also be available for download at the Company’s website following the event.
